vs
Thermon Group Holdings, Inc.（THR）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Thermon Group Holdings, Inc.的季度营收约是再鼎医药的1.2倍（$147.3M vs $127.1M），再鼎医药同比增速更快（17.1% vs 9.6%），Thermon Group Holdings, Inc.自由现金流更多（$13.1M vs $-26.7M）
Thermon Group Holdings是全球专业热管理解决方案供应商，主打伴热系统、加热电缆、温控监测设备及相关安装支持服务，服务油气、化工、发电、食品饮料等核心工业领域，业务覆盖北美、欧洲、亚太、拉美等全球主要市场。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
THR vs ZLAB — 直观对比
营收规模更大
THR
是对方的1.2倍
$127.1M
营收增速更快
ZLAB
高出7.5%
9.6%
自由现金流更多
THR
多$39.8M
$-26.7M
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $147.3M | $127.1M |
| 净利润 | $18.3M | — |
| 毛利率 | 46.6% | 51.0% |
| 营业利润率 | 18.1% | -54.6% |
| 净利率 | 12.4% | — |
| 营收同比 | 9.6% | 17.1% |
| 净利润同比 | -1.3% | — |
| 每股收益（稀释后） | $0.55 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收THRZLAB
| Q4 25 | $147.3M | $127.1M | ||
| Q3 25 | $131.7M | $115.4M | ||
| Q2 25 | $108.9M | $109.1M | ||
| Q1 25 | — | $105.7M | ||
| Q4 24 | — | $108.5M | ||
| Q3 24 | — | $101.8M | ||
| Q2 24 | — | $100.1M | ||
| Q1 24 | — | $87.1M |
净利润THRZLAB
| Q4 25 | $18.3M | — | ||
| Q3 25 | $15.0M | $-36.0M | ||
| Q2 25 | $8.6M | $-40.7M | ||
| Q1 25 | — | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-41.7M | ||
| Q2 24 | — | $-80.3M | ||
| Q1 24 | — | $-53.5M |
毛利率THRZLAB
| Q4 25 | 46.6% | 51.0% | ||
| Q3 25 | 46.4% | 59.5% | ||
| Q2 25 | 44.1% | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率THRZLAB
| Q4 25 | 18.1% | -54.6% | ||
| Q3 25 | 16.4% | -42.3% | ||
| Q2 25 | 10.8% | -50.3% | ||
| Q1 25 | — | -53.3% | ||
| Q4 24 | — | -62.6% | ||
| Q3 24 | — | -66.6% | ||
| Q2 24 | — | -76.0% | ||
| Q1 24 | — | -80.7% |
净利率THRZLAB
| Q4 25 | 12.4% | — | ||
| Q3 25 | 11.4% | -31.2% | ||
| Q2 25 | 7.9% | -37.3% | ||
| Q1 25 | — | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -40.9% | ||
| Q2 24 | — | -80.2% | ||
| Q1 24 | — | -61.4% |
每股收益（稀释后）THRZLAB
| Q4 25 | $0.55 | $-0.05 | ||
| Q3 25 | $0.45 | $-0.03 | ||
| Q2 25 | $0.26 | $-0.04 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $-0.08 | ||
| Q1 24 | — | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $46.9M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $538.7M | $715.5M |
| 总资产 | $816.7M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资THRZLAB
| Q4 25 | $46.9M | $689.6M | ||
| Q3 25 | $29.7M | $717.2M | ||
| Q2 25 | $36.5M | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M | ||
| Q1 24 | — | $650.8M |
股东权益THRZLAB
| Q4 25 | $538.7M | $715.5M | ||
| Q3 25 | $515.2M | $759.9M | ||
| Q2 25 | $509.3M | $791.7M | ||
| Q1 25 | — | $810.8M | ||
| Q4 24 | — | $840.9M | ||
| Q3 24 | — | $667.7M | ||
| Q2 24 | — | $704.2M | ||
| Q1 24 | — | $762.2M |
总资产THRZLAB
| Q4 25 | $816.7M | $1.2B | ||
| Q3 25 | $778.2M | $1.2B | ||
| Q2 25 | $765.3M | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $985.3M | ||
| Q2 24 | — | $987.4M | ||
| Q1 24 | — | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.0M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $13.1M | $-26.7M |
| 自由现金流率自由现金流/营收 | 8.9% | -21.0% |
| 资本支出强度资本支出/营收 | 3.3% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.98× | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流THRZLAB
| Q4 25 | $18.0M | $-26.0M | ||
| Q3 25 | $7.4M | $-32.0M | ||
| Q2 25 | $10.7M | $-31.0M | ||
| Q1 25 | — | $-61.7M | ||
| Q4 24 | — | $-55.8M | ||
| Q3 24 | — | $-26.8M | ||
| Q2 24 | — | $-42.2M | ||
| Q1 24 | — | $-90.1M |
自由现金流THRZLAB
| Q4 25 | $13.1M | $-26.7M | ||
| Q3 25 | $4.4M | $-35.0M | ||
| Q2 25 | $8.3M | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | — | $-42.9M | ||
| Q1 24 | — | $-91.1M |
自由现金流率THRZLAB
| Q4 25 | 8.9% | -21.0% | ||
| Q3 25 | 3.3% | -30.4% | ||
| Q2 25 | 7.6% | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | -42.9% | ||
| Q1 24 | — | -104.5% |
资本支出强度THRZLAB
| Q4 25 | 3.3% | 0.5% | ||
| Q3 25 | 2.3% | 2.6% | ||
| Q2 25 | 2.2% | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 1.1% |
现金转化率THRZLAB
| Q4 25 | 0.98× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
THR
| Other | $73.7M | 50% |
| Transferred At Point In Time | $56.1M | 38% |
| Transferred Over Time | $17.5M | 12% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
